# Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension

> **NCT04528056** · PHASE1,PHASE2 · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Sulfasalazine
- **DRUG:** Ambrisentan
- **DRUG:** Sulfasalazine's placebo
- **DRUG:** Ambrisentan's placebo

## Key facts

- **NCT ID:** NCT04528056
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2020-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04528056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04528056, "Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04528056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*